Selenium-based compounds: Emerging players in the ever-unfolding story of SOD1 in amyotrophic lateral sclerosis

EBioMedicine. 2020 Sep:59:102997. doi: 10.1016/j.ebiom.2020.102997. Epub 2020 Sep 3.

Authors

Justin J Yerbury¹, Neil R Cashman²

Affiliations

¹ Illawarra Health and Medical Research Institute, and School of Chemistry and Molecular Bioscience, Faculty of Science, Medicine and Health, University of Wollongong, Wollongong, NSW, Australia.
² Djavad Mowafaghian Centre for Brain Health, University of British Columbia, Vancouver, BC, Canada. Electronic address: Neil.Cashman@vch.ca.

No abstract available

MeSH terms

Amyotrophic Lateral Sclerosis / drug therapy
Amyotrophic Lateral Sclerosis / genetics*
Amyotrophic Lateral Sclerosis / physiopathology
Animals
Azoles / administration & dosage
Azoles / pharmacology*
Body Weight / drug effects
Disease Models, Animal
Humans
Isoindoles
Motor Activity / drug effects
Mutation
Organoselenium Compounds / administration & dosage
Organoselenium Compounds / pharmacology*
Protein Folding / drug effects*
Superoxide Dismutase-1 / chemistry*
Superoxide Dismutase-1 / genetics*

Substances

Azoles
Isoindoles
Organoselenium Compounds
SOD1 protein, human
ebselen
Superoxide Dismutase-1